Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Unternehmen & Branche
| Name | Corvus Pharmaceuticals, Inc. |
|---|---|
| Ticker | CRVS |
| CIK | 0001626971 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,28 Mrd. USD |
| Beta | 0,97 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -15,283,000 | -0.53 | 71,119,000 | 61,205,000 | |
| 2025-09-30 | 10-Q | -10,157,000 | -0.12 | 80,474,000 | 71,768,000 | |
| 2025-06-30 | 10-Q | -7,998,000 | -0.10 | 89,461,000 | 80,228,000 | |
| 2025-03-31 | 10-Q | 15,193,000 | -0.13 | 59,438,000 | 49,325,000 | |
| 2024-12-31 | 10-K | -62,293,000 | -1.02 | 68,907,000 | 32,568,000 | |
| 2024-09-30 | 10-Q | -40,217,000 | -0.60 | 58,815,000 | 12,409,000 | |
| 2024-06-30 | 10-Q | -4,262,000 | -0.07 | 64,561,000 | 51,226,000 | |
| 2024-03-31 | 10-Q | -5,701,000 | -0.12 | 40,084,000 | 33,364,000 | |
| 2023-12-31 | 10-K | -27,029,000 | -0.56 | 45,553,000 | 38,684,000 | |
| 2023-09-30 | 10-Q | -6,000,000 | -0.12 | 51,942,000 | 44,289,000 | |
| 2023-06-30 | 10-Q | -6,503,000 | -0.14 | 58,041,000 | 49,483,000 | |
| 2023-03-31 | 10-Q | -7,873,000 | -0.17 | 58,197,000 | 48,867,000 | |
| 2022-12-31 | 10-K | -41,307,000 | -0.89 | 68,240,000 | 56,115,000 | |
| 2022-09-30 | 10-Q | -14,831,000 | -0.32 | 80,348,000 | 64,681,000 | |
| 2022-06-30 | 10-Q | -8,363,000 | -0.18 | 92,541,000 | 80,386,000 | |
| 2022-03-31 | 10-Q | -8,297,000 | -0.18 | 101,290,000 | 89,722,000 | |
| 2021-12-31 | 10-K | -43,241,000 | -0.20 | 109,455,000 | 97,162,000 | |
| 2021-09-30 | 10-Q | -10,673,000 | -0.24 | 119,323,000 | 105,148,000 | |
| 2021-06-30 | 10-Q | -11,752,000 | -0.28 | 109,394,000 | 96,403,000 | |
| 2021-03-31 | 10-Q | -11,580,000 | -0.34 | 109,236,000 | 94,385,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-06-27 | Thompson Peter A. | Director, 10% Owner | Open Market Sale | -1,176,332 | 4.16 | -4,891,894.26 | -100,0% | |
| 2025-06-27 | ORBIMED ADVISORS LLC | Director, 10% Owner | Open Market Sale | -1,176,332 | 4.16 | -4,891,894.26 | -100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.